Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 Diabetes: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 Diabetes


DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 45th Annual

Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)


Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for

Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progressionhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression


Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the

Agilent Reports Second-Quarter Fiscal Year 2024 Financial ResultsPhoto, wide shot, wide-angle lens, soft focus,  Amusement park, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-9ykfBOFTwqbOHnaukQ2bUqdm.png?st=2023-05-13T13%3A50%3A52Z&se=2023-05-13T15%3A50%3A52Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-12T20%3A43%3A22Z&ske=2023-05-13T20%3A43%3A22Z&sks=b&skv=2021-08-06&sig=G2Gltvd1Lg2exXRILeKuP5%2BTSWMna0SOjxb75jCyrG0%3D
Agilent Reports Second-Quarter Fiscal Year 2024 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core(1) compared to the second quarter

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth

Agilent Announces Hans E. Bishop Has Stepped Down from Board of Directors:
Agilent Announces Hans E. Bishop Has Stepped Down from Board of Directors


Agilent Technologies Inc. (NYSE: A) today announced that Hans E. Bishop, president and co-founder of Altos Labs, has stepped down from serving on Agilent’s board of directors.



Bishop joined

Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence:
Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence


Agilent Technologies Inc., (NYSE: A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system

QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Agilent Announces Cash Dividend of 23.6 Cents per Share: https://unsplash.com/photos/WUehAgqO5hE
Agilent Announces Cash Dividend of 23.6 Cents per Share


Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on July 24, 2024, to all shareholders of record as of the close of

Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes


DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily

Agilent to Participate in Jefferies Global Healthcare ConferencePhoto, wide shot, wide-angle lens, soft focus,  Car rental company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Edward Burtynsky: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-C39HK7mRtkD4E8dIGhNKdJKJ.png?st=2023-05-14T13%3A30%3A04Z&se=2023-05-14T15%3A30%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-13T20%3A57%3A44Z&ske=2023-05-14T20%3A57%3A44Z&sks=b&skv=2021-08-06&sig=c7kEiWtHt1KibrlL7jP9uEmEuV%2BuAnv1nRBACXoedSk%3D
Agilent to Participate in Jefferies Global Healthcare Conference


Agilent Technologies Inc. (NYSE: A) today announced that CFO Bob McMahon will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 5, at

Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
CenterWell Specialty Pharmacy Wins National Patient Choice Award: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
CenterWell Specialty Pharmacy Wins National Patient Choice Award


CenterWell Specialty Pharmacy has received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the sixth time in seven years. The award recognizes best-in-class customer

Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
QuidelOrtho Reports First Quarter 2024 Financial Results: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports First Quarter 2024 Financial Results


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and

Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Pfizer Announces New Chief Strategy and Innovation Officerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces New Chief Strategy and Innovation Officer


Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s

Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29Photo, wide shot, wide-angle lens, soft focus,  Auto parts supplier, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-XjwbnkgTrFCFx6Y3gLbqZBCj.png?st=2023-05-13T09%3A21%3A52Z&se=2023-05-13T11%3A21%3A52Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-13T06%3A55%3A39Z&ske=2023-05-14T06%3A55%3A39Z&sks=b&skv=2021-08-06&sig=wJlbn/o%2BieTjclaQNRsJc%2BDDZieC0UCS6BPi5tapxAA%3D
Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29


Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution:
Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution


Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold